MO
Mamitaro Ohtsuki

Elite Scholar

355
Works
10,125
Citations
44
H-Index
Search Authors
Author Statistics
External Links
OpenAlex Profile ORCID Profile

Mamitaro Ohtsuki

Also known as: M OHTSUKI, M Ohtsuki, M. Ohtsuki, MAMITARO OHTSUKI, Mamitaro OHTSUKI

355

Total Works

10,125

Citations

44

H-Index

147

i10-Index

Citation & Works Trend by Year
34 years active
Top Research Topics
Dermatology and Skin Diseases (169) Psoriasis: Treatment and Pathogenesis (146) Spondyloarthritis Studies and Treatments (108) Skin and Cellular Biology Research (35) IL-33, ST2, and ILC Pathways (35)
Recent Publications
15 shown
Year Publication Title Citations Action
2026 Refractory Psoriatic Lesions in Japanese Patients Before and After Switching Biologics The Journal of Dermatology 0
2026 Long‐Term Follow‐Up of Epidermolysis Bullosa Acquisita with Fluctuations in Serum Cytokine Levels: A Case Report The Journal of Dermatology 0
2026 Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5‐Year Analysis of the Phase 3 POETYK PSO ‐1, PSO ‐4, and Long‐Term Extension Trials The Journal of Dermatology 0
2026 Remarkable effect of nivolumab on late liver metastasis recurrence in advanced malignant melanoma Journal of Cutaneous Immunology and Allergy 0
2026 Refractory Psoriatic Lesions in Japanese Patients With Biologics The Journal of Dermatology 1
2026 Acid ceramidase overactivity drives ceramide loss, leading to atopic dry skin and Th2‐skewed immune polarization The Journal of Pathology 1
2025 Prospective, Open‐Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics The Journal of Dermatology 2
2025 Extramammary Paget’s disease in situ of the scrotum and penis with cervical lymph node metastasis of unknown origin European Journal of Dermatology 0
2025 Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results American Journal of Clinical Dermatology 13
2025 Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics The Journal of Dermatology 0
2025 Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study The Journal of Dermatology 1
2025 Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months Dermatology and Therapy 2
2025 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In‐Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO ‐4 Trial The Journal of Dermatology 4
2025 Pachydermoperiostosis successfully treated with celecoxib The Journal of Dermatology 0
2025 Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance The Journal of Dermatology 5

Data source: OpenAlex API